Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients - The Dutch CONvective TRAnsport STudy (CONTRAST): Rationale and design of a randomised controlled trial [ISRCTN38365125]

Current Controlled Trials in Cardiovascular Medicine

Volumn 6, Issue , 2005, Pages

  Penne, E Lars ^a   Blankestijn, Peter J ^a   Bots, Michiel L ^a   van den Dorpel, Marinus A ^b   Grooteman, Muriel P ^c   Nubé, Menso J ^c,d   van der Tweel, Ingeborg ^e   ter Wee, Piet M ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Medisch Centrum Rijnmond Zuid   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Location Alkmaar   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cardiovascular disease; Convective transport; End stage renal disease; Hemodiafiltration; Hemodialysis; Middle molecules; Mortality; Outcome

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS MEMBRANE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; MULTICENTER STUDY; ONLINE SYSTEM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STANDARD; SURVIVAL; TREATMENT OUTCOME;

EID: 27544447927     PISSN: 14686694     EISSN: 14686694     Source Type: Journal    
DOI: 10.1186/1468-6708-6-8     Document Type: Article

References (40)

1. Parfrey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999, 10:1606-1615.
2. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 342:1478-1483.
3. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000, 58:353-362.
4. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002, 62:1524-1538
5. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres, A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML: Uremic toxicity: present state of the art. Int J Artif Organs 2001, 24:695-725.
6. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999, 55:648-658.
7. Vanholder R, Giorieux G, Lameire N: Uraemic toxins and cardiovascular disease. Nephrol Dial Transplant 2003, 18:463-466.
8. Beerenhout CH, Kooman JP, Luik AJ, Jeuken-Mertens SG, Van Der Sande FM, Leunissen KM: Optimizing renal replacement therapy - a case for online filtration therapies? Nephrol Dial Transplant 2002, 17:2065-2070.
9. Lornoy W, Becaus I, Billiouw JM, Sierens L. Van Malderen P, D'Haenens P: On-line haemodiafiltration. Remarkable removal of beta2-microglobulin. Long-term clinical observations. Nephrol Dial Transplant 2000, 15 Suppl 1:49-54.
10. Lin CL, Yang CW, Chiang CC, Chang CT, Huang CC: Long-term on-line hemodiafiltration reduces predialysis beta-2-microglobalin levels in chronic hemodialysis patients. Blood Purif 2001, 19:301-307.
11. Lin CL, Huang CC, Yu CC, Yang HY, Chuang FR, Yang CW: Reduction of advanced glycation end product levels by on-line hemodiafiltration in long-term hemodialysis patients. Am J Kidney Dis 2003, 42:324-531.
12. Van Tellingen A, Grooteman MP, Schoorl M, ter Wee PM, Bartels PC, Schoorl M, Van Der PT, Nube MJ: Enhanced long-term reduction of plasma leptin concentrations by super-flux polysulfone dialysers. Nephrol Dial Transplant 2004, 19:1198-1203.
13. Ward RA, Schmidt B, Hullin J, Hillebrand GF, Samtleben W: A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study. J Am Soc Nephrol 2000, 11:2344-2350.
14. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y: Removal of the protein-bound solute p-cresol by convective transport: a randomized crossover study. Am J Kidney Dis 2004, 44:278-285.
15. Van Tellingen A, Grooteman MP, Bartels PC, Van Limbeek J, Van Guldener C, Wee PM, Nube MJ: Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients. Kidney Int 2001, 59:342-347.
16. Minutolo R, Bellizzi V, Cioffi M, Iodice C, Giannattasio P, Andreucci M, Terracciano V, Di Iorio BR, Conte G, De Nicola L: Postdialytic rebound of serum phosphorus: pathogenetic and clinical insights. J Am Soc Nephrol 2002, 13:1046-1054.
17. Zehnder C, Gutzwilier JP, Renggli K: Hemodiafiltration - a new treatment option for hyperphosphatemia in hemodialysis patients. Clin Nephrol 1999, 52:152-159.
18. Gil C, Lucas C, Possante C, Jorge C, Gomes F, Candeias M, Lages H, Arranhado E, Ferreira A: On-line haemodiafiltration decreases serum TNFalpha levels in haemodialysis patients. Nephrol Dial Transplant 2003 18:447-448.
19. Ward RA: Ultrapure dialysate: a desirable and achievable goal for routine hemodialysis. Semin Dial 2000, 13:378-380.
20. Horl WH: Hemodialysis membranes: interleukins, biocompatibility, and middle molecules. J Am Soc Nephrol 2002, 13 Suppl 1:S62-S71.
21. Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, Gillespie BW, Depner TA, Klassen P, Port FK: Patients recieving hemodiafiltration or hemofiltration have lower mortality risk than patients recieving hemodialysis without replacement fluid (HD) in Europe: The Dialysis Outcomes and Practice Patterns Study (DOPPS) [abstract]. J Am Soc Nephrol 2003, 14:31A.
22. Locatell, F, Marcelli D, Conte F, Limido A, Malberti F, Spotti D: Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Traplanto. Kidney Int 1999, 55:286-293.
23. Wizemann V, Lotz C, Techert F, Uthoff S: On-line haemodiafiltration versus low-flux haemodialysis. A prospective randomized study. Nephrol Dial Transplant 2000, 15 Suppl 1:43-48.
24. Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G, Orlandini C, Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996, 50:1293-1302.
25. Ledebo I: On-line hemodiafiltration: technique and therapy. Adv Ren Replace Ther 1999, 6:195-208.
26. Canaud B, Bosc JY, Leray H, Stec F: Microbiological purity of dialysate for on-line substitution fluid preparation. Nephrol Dial Transplant 2000 15 Suppl 2:21-30.
27. Simons PC, Algra A, Bots ML, Grobbee DE, van der GY: Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ART erial disease). Circulation 1999, 100:951-957.
28. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977, 55:613-618.
29. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I,.: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms, J Am Soc Echocardiogr 1989, 2:358-367.
30. Oren A, Vos LE, Uiterwaal CS, Grobbee DE, Bots ML: Cardiovascular risk factors and Increased carotid intima-media thickness in healthy young adults: the Atherosclerosis Risk in Young Adults (ARYA) Study. Arch Intern Med 2003, 163:1787-1792.
31. Crouse JRIII, Grobbee DE, O'Leary DH, Bots ML. Evans GW, Palmer MK, Riley WA, Raichlen JS: Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis - the rationale and methodology of the METEOR study. Cardiovasc Drugs Ther 2004, 18:231-238.
32. Bots M L, Evans GW, Riley W, Meijer R, McBride KH, Paskett ED, Helmond FA, Grobbee DE: The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics. Control Clin Trials 2003, 24:752-775.
33. Blacher J, Guerin AP, Pannier B. Marchais SJ, Safar ME, London GM: Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999, 99:2434-2439.
34. Lebrun CE, van der Schouw YT, Bak AA, de Jong FH, Pols HA, Grobbee DE, Lamberts SW, Bots ML; Arterial stiffness in postmenopausal women: determinants of pulse wave velocity. J Hypertens 2002, 20:2165-2172.
35. Locatelli F, Fouque D, Heimburger O, Drueke TB, Cannata-Andia JB, Horl WH, Ritz E: Nutritional status in dialysis atients: a European consensus. Nephrol Dial Transplant 2002, 17:563-572.
36. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB: Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 1994, 3:329-338.
37. Korevaar JC, Merkus MP, Jansen MA, Dekker FW, Boeschoten EW, Krediet RT: Validation of the KDQOL-SF: a dialysis-targeted health measure. Qual Life Res 2002, 11:437-447.
38. Registratie Nierfunctievervanging Nederland (RENINE): Statistisch Jaarverslag 2002. Rotterdam; 2002.
39. Whitehead J: The design and analysis of sequential clinical trials Revised 2nd edition edition. Chichester, John Wiley & Sons; 1997.
40. MPS Research Unit: Pest 4: Operating Manual. Reading (UK): University of Reading; 2000.